Blueprint Medicines Corporation (BPMC)
NASDAQ: BPMC · Real-Time Price · USD
92.25
-2.10 (-2.23%)
Feb 21, 2025, 4:00 PM EST - Market closed
Blueprint Medicines Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
Cash & Equivalents | 102.01 | 71.29 | 119.71 | 209.95 | 684.64 | Upgrade
|
Short-Term Investments | 513.47 | 639.36 | 825.28 | 267.17 | 187.21 | Upgrade
|
Cash & Short-Term Investments | 615.49 | 710.64 | 944.99 | 477.11 | 871.85 | Upgrade
|
Cash Growth | -13.39% | -24.80% | 98.06% | -45.28% | 80.30% | Upgrade
|
Receivables | 77.61 | 43.18 | 36.94 | 37.03 | 25.31 | Upgrade
|
Inventory | 13.61 | 21.22 | 29.7 | 21.82 | 8.58 | Upgrade
|
Prepaid Expenses | 35.97 | 33.35 | 35.02 | 18.06 | 22.02 | Upgrade
|
Total Current Assets | 742.68 | 808.39 | 1,047 | 554.03 | 927.76 | Upgrade
|
Property, Plant & Equipment | 100.77 | 115.65 | 115.2 | 120.86 | 101.67 | Upgrade
|
Long-Term Investments | 277.15 | 84.32 | 161.27 | 557.53 | 677.87 | Upgrade
|
Other Long-Term Assets | 59.21 | 40.89 | 26.78 | 19.81 | 11.09 | Upgrade
|
Total Assets | 1,180 | 1,049 | 1,350 | 1,252 | 1,718 | Upgrade
|
Accounts Payable | 6.79 | 4.71 | 2.73 | 8.33 | 4.37 | Upgrade
|
Accrued Expenses | 102.27 | 110.53 | 122.08 | 117.9 | 104.97 | Upgrade
|
Current Portion of Long-Term Debt | 105.57 | 69.48 | 34.14 | - | - | Upgrade
|
Current Portion of Leases | 13.35 | 11.93 | 10.58 | 8.09 | 7.94 | Upgrade
|
Current Unearned Revenue | 2.01 | 0.81 | 4.67 | 11.51 | 12.56 | Upgrade
|
Other Current Liabilities | 30.82 | 17.47 | 9.05 | 3.93 | 0.97 | Upgrade
|
Total Current Liabilities | 260.8 | 214.92 | 183.23 | 149.77 | 130.8 | Upgrade
|
Long-Term Debt | 536.58 | 610.96 | 535.28 | - | - | Upgrade
|
Long-Term Leases | 68.79 | 81.75 | 92.79 | 103.32 | 81.67 | Upgrade
|
Long-Term Unearned Revenue | 8.19 | 4.79 | 13.62 | 25.07 | 28.6 | Upgrade
|
Other Long-Term Liabilities | 6.79 | 6.21 | 10.3 | 3.34 | 7.24 | Upgrade
|
Total Liabilities | 881.15 | 918.64 | 835.23 | 281.49 | 248.31 | Upgrade
|
Common Stock | 0.06 | 0.06 | 0.06 | 0.06 | 0.06 | Upgrade
|
Additional Paid-In Capital | 2,709 | 2,474 | 2,358 | 2,250 | 2,107 | Upgrade
|
Retained Earnings | -2,407 | -2,340 | -1,833 | -1,275 | -631.36 | Upgrade
|
Comprehensive Income & Other | -3.55 | -3.5 | -10.44 | -4.13 | -5.21 | Upgrade
|
Total Common Equity | 298.67 | 130.61 | 514.68 | 970.74 | 1,470 | Upgrade
|
Shareholders' Equity | 298.67 | 130.61 | 514.68 | 970.74 | 1,470 | Upgrade
|
Total Liabilities & Equity | 1,180 | 1,049 | 1,350 | 1,252 | 1,718 | Upgrade
|
Total Debt | 724.28 | 774.12 | 672.78 | 111.41 | 89.6 | Upgrade
|
Net Cash (Debt) | 139.66 | -6.95 | 405.69 | 923.24 | 1,460 | Upgrade
|
Net Cash Growth | - | - | -56.06% | -36.77% | 223.03% | Upgrade
|
Net Cash Per Share | 2.22 | -0.11 | 6.80 | 15.78 | 26.00 | Upgrade
|
Filing Date Shares Outstanding | 63.91 | 61.23 | 59.98 | 59.2 | 57.96 | Upgrade
|
Total Common Shares Outstanding | 63.71 | 61.15 | 59.96 | 59.14 | 57.79 | Upgrade
|
Working Capital | 481.88 | 593.47 | 863.42 | 404.26 | 796.96 | Upgrade
|
Book Value Per Share | 4.69 | 2.14 | 8.58 | 16.41 | 25.44 | Upgrade
|
Tangible Book Value | 298.67 | 130.61 | 514.68 | 970.74 | 1,470 | Upgrade
|
Tangible Book Value Per Share | 4.69 | 2.14 | 8.58 | 16.41 | 25.44 | Upgrade
|
Machinery | 32.42 | 27.98 | 21.32 | 18.55 | 16.35 | Upgrade
|
Construction In Progress | 0.24 | 9.51 | 1.61 | 0.21 | 0.15 | Upgrade
|
Leasehold Improvements | 50.79 | 42.3 | 41.05 | 36.95 | 36.95 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.